Measuring the Effectiveness of Cabozantinib in Advanced Lung Cancer with Gene Changes

Recruiting · Phase 2 · Non-Small Cell Lung Cancer · New Jersey and New York

Check if I qualify View on ClinicalTrials.gov

About this trial

This study is looking at how well cabozantinib works for patients with advanced non-small cell lung cancer that has specific gene changes. These changes include RET, ROS1, or NTRK fusions, or increased MET or AXL activity. Cabozantinib is a medication that helps stop cancer cells from growing. The goal is to see if this medicine can help shrink the cancer and keep it from getting bigger.

The trial's ID number is NCT01639508. It is a Phase 2 trial, which means it is looking at how well the treatment works and how safe it is. The study is regulated by the FDA and hopes to include about 86 participants.

Who can join

Adults aged 18 and older can join this study. It is open to both men and women with advanced non-small cell lung cancer. Participants must have specific gene changes in their tumors. The study team will check to see if you meet all the requirements before you can join.

Condition

Non-Small Cell Lung Cancer

Age group

Adult, Older adult

Sex

All sexes

The study team makes the final call on eligibility.

What happens in the study

Everyone in the study will receive cabozantinib, which they will take by mouth daily for 28 days. Participants will continue taking the medication as long as their cancer does not get worse and they do not have side effects that are too tough to handle. There are different groups based on the type of gene changes in their tumors.